Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports

Mycoses. 1997 Dec;40(9-10):359-61. doi: 10.1111/j.1439-0507.1997.tb00250.x.

Abstract

Despite its common adverse effects intravenous (i.v.) amphotericin B is an indispensable antifungal drug in childhood oncology. We report here on three cases of painful cyanotic Raynaud's phenomenon after i.v. administration or inhalation of amphotericin B. A liposomal i.v. preparation of amphotericin B was well tolerated by the infants. Spasms of peripheral vessels mediated by thromboxane A2 could be responsible for the Raynaud's phenomenon. Hence, inhibitors of prostaglandin synthesis are suggested for therapy.

Publication types

  • Case Reports

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Amphotericin B / adverse effects*
  • Amphotericin B / therapeutic use
  • Antifungal Agents / adverse effects*
  • Antifungal Agents / therapeutic use
  • Child
  • Cyanosis / chemically induced*
  • Female
  • Humans
  • Injections, Intravenous
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myelomonocytic, Chronic / drug therapy
  • Liposomes / therapeutic use*
  • Lymphoma, Large-Cell, Anaplastic / drug therapy
  • Male
  • Raynaud Disease / chemically induced*

Substances

  • Antifungal Agents
  • Liposomes
  • Amphotericin B